




Test Update 958

Posted Date 06/03/2026

Effective Date 05/11/2026

Test Name [Amyloid Protein Identification, Paraffin, LC-MS/MS](#)

Update Type [Specimen collection or handling and/or storage changed](#)

CPT Code 88313, 82542, 88380

TEST REQUIREMENT CHANGE

Amyloid Protein Identification, Paraffin, LC-MS/MS

Order Code: AMPIP

Fee Code: TBD (CPT 88313, (82542, 88380))

Reference Lab: Mayo AMPIP

Effective May 11, 2026, Mayo Clinic Laboratories test, AMPIP, testing of tenosynovial specimens is only available on patients aged ≥ 75 years. This approach is based on current evidence regarding ATTR amyloidosis. Tenosynovial ATTR deposition is considered a potential early marker (risk factor) for subsequent cardiac involvement; however, it does not in itself warrant treatment. Only a minority of patients with tenosynovial ATTR go on to develop cardiac ATTR, and progression—when it occurs—may take many years to decades. By restricting testing for this specimen type to a higher-risk age group, we aim to prioritize tenosynovial cases with the greatest likelihood of clinically actionable cardiac involvement, while also ensuring capacity for other specimen types with more immediate clinical impact. Regardless of amyloid type, the presence of tenosynovial amyloid raises the possibility of underlying cardiac amyloidosis (Westin O, et al. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977). Clinicopathologic correlation is recommended, with consideration of cardiology consultation as clinically indicated.

[View PDF](#)